Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Progyny, Inc.
  6. Summary
    PGNY   US74340E1038

PROGYNY, INC.

(PGNY)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/20/2022 01/21/2022 01/24/2022 01/25/2022 01/26/2022 Date
38.24(c) 36.88(c) 38.16(c) 37.89(c) 38.87 Last
924 083 844 273 1 173 280 826 969 530 620 Volume
-0.36% -3.56% +3.47% -0.71% +2.59% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 508 M - -
Net income 2021 54,7 M - -
Net cash position 2021 174 M - -
P/E ratio 2021 72,3x
Yield 2021 -
Sales 2022 757 M - -
Net income 2022 59,5 M - -
Net cash position 2022 254 M - -
P/E ratio 2022 75,7x
Yield 2022 -
Capitalization 3 426 M 3 426 M -
EV / Sales 2021 6,40x
EV / Sales 2022 4,19x
Nbr of Employees 210
Free-Float -
More Financials
Company
Progyny Inc is a United States-based fertility benefits management company. The Company specialized in fertility and family building benefits solutions in the United States. The Company offers patients a benefits solution with education and guidance from a patient care advocate and network of fertility specialists. Progyny also aims to reduce healthcare costs for employers through their operations. 
Sector
Managed Healthcare
Calendar
03/10Earnings Release
More about the company
Ratings of Progyny, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about PROGYNY, INC.
01/21PROGYNY : Initial Statement of Beneficial Ownership (Form 3)
PU
01/19Berenberg Bank Adjusts Progyny's Price Target to $71 From $80, Maintains Buy Rating
MT
01/11PROGYNY WEBINAR : Family Building and Your Progyny Benefit 101
PU
01/11Progyny, Inc. Provides Revenue Guidance for the Year 2022
CI
01/06INSIDER SELL : Progyny
MT
01/05Progyny, Inc. to Present at the 40th Annual J.P. Morgan Healthcare Conference
AQ
01/04INSIDER SELL : Progyny
MT
2021INSIDER SELL : Progyny
MT
2021INSIDER SELL : Progyny
MT
2021PROGYNY : Corporate Social Responsibility Report 2.6 MB
PU
2021Jefferies Starts Progyny at Buy with $60 Price Target
MT
2021INSIDER SELL : Progyny
MT
2021Progyny Shares Drop After Citigroup Downgrade
MT
2021INSIDER SELL : Progyny
MT
2021Citigroup Downgrades Progyny to Neutral From Buy, Adjusts Price Target to $64 From $60
MT
More news
News in other languages on PROGYNY, INC.
01/11Progyny, Inc. fournit des prévisions de revenus pour l'année 2022
01/06VENTE D'INITIÉS : Progyny
01/04VENTE D'INITIÉS : Progyny
2021VENTE D'INITIÉS : Progyny
2021Les actions de Progyny chutent après la dégradation de Citigroup
More news
Analyst Recommendations on PROGYNY, INC.
More recommendations
Chart PROGYNY, INC.
Duration : Period :
Progyny, Inc. Technical Analysis Chart | PGNY | US74340E1038 | MarketScreener
Technical analysis trends PROGYNY, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 37,89 $
Average target price 68,50 $
Spread / Average Target 80,8%
EPS Revisions
Managers and Directors
Peter Anevski Chief Executive Officer & Director
Michael Sturmer President
Mark Livingston Chief Financial Officer
David J. Schlanger Executive Chairman
Alan B. Copperman Medical Director
Sector and Competitors
1st jan.Capi. (M$)
PROGYNY, INC.-24.75%3 426
UNITEDHEALTH GROUP-9.02%430 275
ANTHEM, INC.-5.26%106 595
CIGNA CORPORATION2.23%77 799
HUMANA INC.-19.15%48 206
CENTENE CORPORATION-7.32%44 562